Garth was President and CEO of Mimetogen Pharmaceuticals, a biotechnology company developing novel neuroprotective and neurostimulatory compounds for the treatment of ocular diseases. Prior to Mimetogen, Dr. Cumberlidge served as President & CEO of Qbiogene, a company providing life sciences research products and custom cGMP manufacturing services to academic, biotechnology and pharmaceutical researchers worldwide. Cumberlidge holds degrees in Biochemistry and Genetics from the University of London (U.K.) and in Molecular Genetics from the Max-Planck-Institute for Molecular Genetics, Berlin (Germany).